$VTVT
vTv Therapeutics Inc.

2020 Q1 Form 10-Q Financial Statement

#000156459020022936 Filed on May 07, 2020

View on sec.gov

Income Statement

Concept 2020 Q1 2019 Q1
Revenue $8.000K $921.0K
YoY Change -99.13% -55.38%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $2.450M $2.390M
YoY Change 2.51% 5.75%
% of Gross Profit
Research & Development $4.200M $2.820M
YoY Change 48.94% -68.46%
% of Gross Profit
Depreciation & Amortization $27.00K $8.000K
YoY Change 237.5% -80.95%
% of Gross Profit
Operating Expenses $6.654M $5.210M
YoY Change 27.72% -53.48%
Operating Profit -$6.646M -$4.287M
YoY Change 55.03% -53.07%
Interest Expense $168.0K $626.0K
YoY Change -73.16% -174.52%
% of Operating Profit
Other Income/Expense, Net -$360.0K $920.0K
YoY Change -139.13% 9100.0%
Pretax Income -$7.165M -$3.982M
YoY Change 79.93% -60.02%
Income Tax $0.00 $0.00
% Of Pretax Income
Net Earnings -$4.724M -$2.155M
YoY Change 119.21% -27.0%
Net Earnings / Revenue -59050.0% -233.98%
Basic Earnings Per Share
Diluted Earnings Per Share -$108.6K -$94.49K
COMMON SHARES
Basic Shares Outstanding
Diluted Shares Outstanding

Balance Sheet

Concept 2020 Q1 2019 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $400.0K $5.000M
YoY Change -92.0% -23.08%
Cash & Equivalents $2.906M $7.459M
Short-Term Investments
Other Short-Term Assets $3.100M $400.0K
YoY Change 675.0% -85.71%
Inventory
Prepaid Expenses
Receivables $0.00
Other Receivables $0.00
Total Short-Term Assets $3.500M $5.400M
YoY Change -35.19% -43.16%
LONG-TERM ASSETS
Property, Plant & Equipment $1.000M $300.0K
YoY Change 233.33% 50.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $2.500M $2.500M
YoY Change 0.0% 0.0%
Other Assets $400.0K $2.500M
YoY Change -84.0% 0.0%
Total Long-Term Assets $3.900M $5.300M
YoY Change -26.42% 1.92%
TOTAL ASSETS
Total Short-Term Assets $3.500M $5.400M
Total Long-Term Assets $3.900M $5.300M
Total Assets $7.400M $10.70M
YoY Change -30.84% -27.21%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $7.400M $6.200M
YoY Change 19.35% -45.13%
Accrued Expenses $100.0K $300.0K
YoY Change -66.67%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $4.400M $9.200M
YoY Change -52.17% 35.29%
Total Short-Term Liabilities $12.00M $16.50M
YoY Change -27.27% -38.43%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $4.000M
YoY Change -100.0% -69.47%
Other Long-Term Liabilities $5.000M $2.800M
YoY Change 78.57% -12.5%
Total Long-Term Liabilities $5.000M $6.800M
YoY Change -26.47% -58.28%
TOTAL LIABILITIES
Total Short-Term Liabilities $12.00M $16.50M
Total Long-Term Liabilities $5.000M $6.800M
Total Liabilities $69.20M $68.50M
YoY Change 1.02% -58.1%
SHAREHOLDERS EQUITY
Retained Earnings
YoY Change
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$61.82M -$57.74M
YoY Change
Total Liabilities & Shareholders Equity $7.400M $10.70M
YoY Change -30.84% -27.21%

Cashflow Statement

Concept 2020 Q1 2019 Q1
OPERATING ACTIVITIES
Net Income -$4.724M -$2.155M
YoY Change 119.21% -27.0%
Depreciation, Depletion And Amortization $27.00K $8.000K
YoY Change 237.5% -80.95%
Cash From Operating Activities -$5.560M -$5.450M
YoY Change 2.02% 0.98%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities $0.00
YoY Change -100.0%
Cash From Investing Activities $0.00
YoY Change -100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $5.443M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 4.189M 8.726M
YoY Change -51.99%
NET CHANGE
Cash From Operating Activities -5.560M -5.450M
Cash From Investing Activities 0.000
Cash From Financing Activities 4.189M 8.726M
Net Change In Cash -1.371M 3.276M
YoY Change -141.85% -160.84%
FREE CASH FLOW
Cash From Operating Activities -$5.560M -$5.450M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2020Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2450000
CY2020Q1 vtvt Change In Fair Value Of Warrants Related Party
ChangeInFairValueOfWarrantsRelatedParty
363000
CY2019Q1 us-gaap Minority Interest Change In Redemption Value
MinorityInterestChangeInRedemptionValue
15549000
CY2019Q1 us-gaap Stockholders Equity
StockholdersEquity
-57735000
CY2019Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2386000
CY2020Q1 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
2500000
CY2019Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
5000
CY2020Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period
SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
P10Y
CY2019Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
806000
CY2019Q4 us-gaap Deposits Assets Noncurrent
DepositsAssetsNoncurrent
444000
CY2019Q4 us-gaap Assets
Assets
9266000
CY2019Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
7068000
CY2019Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
110000
CY2019Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
31000
CY2019Q4 us-gaap Notes Payable Current
NotesPayableCurrent
6172000
CY2019Q4 us-gaap Liabilities Current
LiabilitiesCurrent
13381000
CY2019Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
831000
CY2019Q4 us-gaap Due To Related Parties Noncurrent
DueToRelatedPartiesNoncurrent
2601000
CY2019Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
260000
CY2019Q4 us-gaap Liabilities
Liabilities
18106000
CY2019Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2019Q4 us-gaap Redeemable Noncontrolling Interest Equity Carrying Amount
RedeemableNoncontrollingInterestEquityCarryingAmount
40183000
CY2019Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
183858000
CY2019Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-233522000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
-49023000
CY2019Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
9266000
CY2020Q1 vtvt Other Income Expenses Related Party
OtherIncomeExpensesRelatedParty
-363000
CY2019Q1 vtvt Other Income Expenses Related Party
OtherIncomeExpensesRelatedParty
921000
CY2020Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
12000
CY2019Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
10000
CY2020Q1 us-gaap Interest Expense
InterestExpense
168000
CY2019Q1 us-gaap Interest Expense
InterestExpense
626000
CY2020Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-7165000
CY2019Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-3982000
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-4724000
CY2020Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-4724000
CY2019Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-5883000
CY2020Q1 vtvt Stock Issued During Period Value Conversion Of Convertible Securities Related Party
StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesRelatedParty
6000000
CY2020Q1 us-gaap Minority Interest Change In Redemption Value
MinorityInterestChangeInRedemptionValue
-14454000
CY2019Q1 vtvt Stock Issued During Period Under Direct Offering Value
StockIssuedDuringPeriodUnderDirectOfferingValue
5443000
CY2019Q1 vtvt Stock Issued During Period Value Conversion Of Convertible Securities Related Party
StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesRelatedParty
6000000
CY2020Q1 us-gaap Depreciation
Depreciation
27000
CY2019Q1 us-gaap Depreciation
Depreciation
8000
CY2020Q1 us-gaap Share Based Compensation
ShareBasedCompensation
380000
CY2019Q1 us-gaap Share Based Compensation
ShareBasedCompensation
281000
CY2019Q1 vtvt Change In Fair Value Of Warrants Related Party
ChangeInFairValueOfWarrantsRelatedParty
-921000
CY2020Q1 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
47000
CY2019Q1 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
185000
CY2020Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-465000
CY2019Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-1337000
CY2020Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
331000
CY2019Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-1445000
CY2020Q1 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-8000
CY2019Q1 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-913000
CY2020Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-5560000
CY2019Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-5450000
CY2020Q1 vtvt Proceeds From Issuance Of Common Stock To Related Party
ProceedsFromIssuanceOfCommonStockToRelatedParty
6000000
CY2019Q1 vtvt Proceeds From Issuance Of Common Stock To Related Party
ProceedsFromIssuanceOfCommonStockToRelatedParty
6000000
CY2019Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
5443000
CY2020Q1 us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
1811000
CY2019Q1 us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
2717000
CY2020Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
4189000
CY2019Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
8726000
CY2020Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-1371000
CY2019Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
3276000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
4277000
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
4183000
CY2020Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
2906000
CY2019Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
7459000
CY2020Q1 us-gaap Use Of Estimates
UseOfEstimates
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Use of Estimates</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On an ongoing basis, the Company evaluates its estimates, including those related to the grant date fair value of equity awards, the fair value of warrants to purchase shares of its Class A Common Stock, the fair value of the Class B Common Stock, the useful lives of property and equipment, the fair value of derivative liabilities, and the fair value of the Company&#8217;s debt, among others. The Company bases its estimates on historical experience and on various other assumptions that it believes to be reasonable, the results of which form the basis for making judgments about the carrying value of assets and liabilities.</p>
CY2020Q1 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Concentration of Credit Risk</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial instruments that potentially expose the Company to concentrations of credit risk consist principally of cash on deposit with multiple financial institutions. The balances of these cash accounts frequently exceed insured limits.</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Two customers represented 100% of the revenue earned during the three months ended March 31, 2019.&nbsp;&nbsp;Revenue for the three months ended March 31, 2020 was insignificant. </p>
CY2020Q1 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
4000000
CY2020Q1 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
2500000
CY2020Q1 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
1056000
CY2019Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
1064000
CY2020Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1
ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
P3Y
CY2019Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.0000
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2531143
CY2020Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2531143
CY2020Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
1821596
CY2020Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P6Y8M12D
CY2020Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber
2461037
CY2020Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
P7Y2M12D
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
6.19
CY2020Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
CY2020Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
CY2020Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
6.19
CY2020Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
7.70
CY2020Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
6.31
CY2020Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
380000
CY2019Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
281000
CY2020Q1 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
3229000
CY2019Q4 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
4896000
CY2019Q4 us-gaap Short Term Borrowings
ShortTermBorrowings
144000
CY2020Q1 vtvt Accreted Final Payment
AccretedFinalPayment
-1179000
CY2019Q4 vtvt Accreted Final Payment
AccretedFinalPayment
-1132000
CY2020Q1 us-gaap Notes Payable
NotesPayable
4408000
CY2019Q4 us-gaap Notes Payable
NotesPayable
6172000
CY2020Q1 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.131
CY2019Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.131
CY2020Q1 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P4Y9M18D
CY2019Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P5Y1M6D
CY2020Q1 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
187000
CY2020Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
255000
CY2020Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
261000
CY2020Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
268000
CY2020Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFive
275000
CY2020Q1 us-gaap Lessee Operating Lease Liability Payments Due After Year Five
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
23000
CY2020Q1 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
1269000
CY2020Q1 vtvt Operating Leases Imputed Interest
OperatingLeasesImputedInterest
338000
CY2020Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
931000
CY2020Q1 vtvt Redeemable Noncontrolling Interest Temporary Equity Redemption Value
RedeemableNoncontrollingInterestTemporaryEquityRedemptionValue
52200000
CY2019Q4 vtvt Redeemable Noncontrolling Interest Temporary Equity Redemption Value
RedeemableNoncontrollingInterestTemporaryEquityRedemptionValue
40200000
CY2020Q1 us-gaap Consolidation Less Than Wholly Owned Subsidiary Parent Ownership Interest Changes Purchase Of Interest By Parent
ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestChangesPurchaseOfInterestByParent
2423000
CY2019Q1 us-gaap Consolidation Less Than Wholly Owned Subsidiary Parent Ownership Interest Changes Purchase Of Interest By Parent
ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestChangesPurchaseOfInterestByParent
7429000
CY2020Q1 us-gaap Consolidation Less Than Wholly Owned Subsidiary Parent Ownership Interest Change Due To Net Income Attributable To Parent And Effects Of Changes Net
ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestChangeDueToNetIncomeAttributableToParentAndEffectsOfChangesNet
-7147000
CY2019Q1 us-gaap Consolidation Less Than Wholly Owned Subsidiary Parent Ownership Interest Change Due To Net Income Attributable To Parent And Effects Of Changes Net
ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestChangeDueToNetIncomeAttributableToParentAndEffectsOfChangesNet
-13312000
CY2020Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2019Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2020Q1 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2019Q1 vtvt Deemed Distribution To Related Party
DeemedDistributionToRelatedParty
3728000
CY2020Q1 vtvt Net Income Loss Available To Common Stockholders Basic And Diluted
NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted
-4724000
CY2019Q1 vtvt Net Income Loss Available To Common Stockholders Basic And Diluted
NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted
-5883000
CY2020Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
30139867
CY2019Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
33833033
CY2020Q1 us-gaap Restructuring And Related Activities Initiation Date
RestructuringAndRelatedActivitiesInitiationDate
2018-12-11
CY2020Q1 us-gaap Payments For Restructuring
PaymentsForRestructuring
300000
CY2020Q1 us-gaap Severance Costs1
SeveranceCosts1
0

Files In Submission

Name View Source Status
0001564590-20-022936-index-headers.html Edgar Link pending
0001564590-20-022936-index.html Edgar Link pending
0001564590-20-022936.txt Edgar Link pending
0001564590-20-022936-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
g1ij3kdt2wp3000001.jpg Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
vtvt-10q_20200331.htm Edgar Link pending
vtvt-20200331.xml Edgar Link completed
vtvt-20200331.xsd Edgar Link pending
vtvt-20200331_cal.xml Edgar Link unprocessable
vtvt-20200331_def.xml Edgar Link unprocessable
vtvt-20200331_lab.xml Edgar Link unprocessable
vtvt-20200331_pre.xml Edgar Link unprocessable
vtvt-ex101_183.htm Edgar Link pending
vtvt-ex311_10.htm Edgar Link pending
vtvt-ex312_6.htm Edgar Link pending
vtvt-ex321_7.htm Edgar Link pending
vtvt-ex322_11.htm Edgar Link pending